# The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score

> **NCT00540891** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 372 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** ALFUZOSIN

## Key facts

- **NCT ID:** NCT00540891
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** 372 (ACTUAL)
- **Last updated:** 2007-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540891, "The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00540891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*